Abstract
The endocannabinoid system comprises the cannabinoid receptors type 1 (CB1) and type 2 (CB2), their endogenous ligands (endocannabinoids) and the whole apparatus appointed of their synthesis and degradation. Recent studies investigated the possibility that drugs targeting the endocannabinoid system might be used to retard or block cancer growth. CB1, CB2 and metabolic enzymes of endocannabinoids, function in the context of lipid rafts, specialized membrane microdomains enriched in cholesterol, sphingolipids and glycosphingolipids which may be important in modulating signal transduction. Here, we analysed the role of lipid rafts/caveolae in the intracellular signaling and trafficking of cannabinoid receptor agonist in cancer cells. Perturbation of lipid rafts/caveolae may in fact represent a useful tool for the development of a novel therapy for endocannabinoids-related diseases, such as cancer. Also, we report the more recent developments of endocannabinoids in cancer drug discovery.
Keywords: Endocannabinoids, cancer, lipid rafts, Δ9-tetrahydrocannabinol, depolarization, capsaicin, 2-arachidonoyl-glycerylether
Mini-Reviews in Medicinal Chemistry
Title:Role of Lipid Rafts/Caveolae in the Anticancer Effect of Endocannabinoids
Volume: 12 Issue: 11
Author(s): Claudia Grimaldi and Anna Capasso
Affiliation:
Keywords: Endocannabinoids, cancer, lipid rafts, Δ9-tetrahydrocannabinol, depolarization, capsaicin, 2-arachidonoyl-glycerylether
Abstract: The endocannabinoid system comprises the cannabinoid receptors type 1 (CB1) and type 2 (CB2), their endogenous ligands (endocannabinoids) and the whole apparatus appointed of their synthesis and degradation. Recent studies investigated the possibility that drugs targeting the endocannabinoid system might be used to retard or block cancer growth. CB1, CB2 and metabolic enzymes of endocannabinoids, function in the context of lipid rafts, specialized membrane microdomains enriched in cholesterol, sphingolipids and glycosphingolipids which may be important in modulating signal transduction. Here, we analysed the role of lipid rafts/caveolae in the intracellular signaling and trafficking of cannabinoid receptor agonist in cancer cells. Perturbation of lipid rafts/caveolae may in fact represent a useful tool for the development of a novel therapy for endocannabinoids-related diseases, such as cancer. Also, we report the more recent developments of endocannabinoids in cancer drug discovery.
Export Options
About this article
Cite this article as:
Grimaldi Claudia and Capasso Anna, Role of Lipid Rafts/Caveolae in the Anticancer Effect of Endocannabinoids, Mini-Reviews in Medicinal Chemistry 2012; 12 (11) . https://dx.doi.org/10.2174/138955712802762158
DOI https://dx.doi.org/10.2174/138955712802762158 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Modulation of intracellular pH in human ovarian cancer.
Current Molecular Medicine Neuroprotective Gene Therapy for Parkinson’s Disease
Current Gene Therapy RO3280: A Novel PLK1 Inhibitor, Suppressed the Proliferation of MCF-7 Breast Cancer Cells Through the Induction of Cell Cycle Arrest at G2/M Point
Anti-Cancer Agents in Medicinal Chemistry Fluorescent Carbon Dots and Nanodiamonds for Biological Imaging: Preparation, Application, Pharmacokinetics and Toxicity
Current Drug Metabolism Signal Transduction Therapy Targeting Apoptosis Pathways in Cancers
Current Signal Transduction Therapy A beta oligomerization A Therapeutic Target for Alzheimers Disease
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Histone and Non-Histone Targets of Dietary Deacetylase Inhibitors
Current Topics in Medicinal Chemistry Immunocal® and Preservation of Glutathione as a Novel Neuroprotective Strategy for Degenerative Disorders of the Nervous System
Recent Patents on CNS Drug Discovery (Discontinued) Circumventing Immune Tolerance Through Epigenetic Modification
Current Pharmaceutical Design Anticonvulsant and Antinociceptive Actions of Novel Adenosine Kinase Inhibitors
Current Topics in Medicinal Chemistry The Role of Epigenetics in Drug Resistance in Cancer
Epigenetic Diagnosis & Therapy (Discontinued) Cardiovascular Side Effects of New Antidepressants and Antipsychotics: New Drugs, old Concerns?
Current Pharmaceutical Design Observations on the Use of the Avian Chorioallantoic Membrane (CAM) Model in Investigations into Angiogenesis
Current Drug Targets - Cardiovascular & Hematological Disorders Statins-Mediated Inhibition of Rho GTPases as a Potential Tool in Anti-Tumor Therapy
Mini-Reviews in Medicinal Chemistry Mechano-Regulation of Alternative Splicing
Current Genomics Binding Sites of Amyloid β-Peptide in Cell Plasma Membrane and Implications for Alzheimers Disease
Current Protein & Peptide Science Rapid Non-genomic Vasodilator Actions of Oestrogens and Sex Steroids
Current Medicinal Chemistry The Histone Deacetylase Inhibitor, MS-275 (Entinostat), Downregulates c-FLIP, Sensitizes Osteosarcoma Cells to FasL, and Induces the Regression of Osteosarcoma Lung Metastases
Current Cancer Drug Targets Paraneoplastic Neurological Syndromes - Diagnosis and Management
Current Pharmaceutical Design Peroxisome Proliferator-Activated Receptor-γ and Its Ligands in the Treatment of Tumors in the Nervous System
Current Stem Cell Research & Therapy